ESMO Breast 2022 | Exciting developments in ADCs for BC presented at ESMO Breast 2022

Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, talks on the latest exciting news presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 meeting, with emphasis on developments in antibody-drug conjugates (ADCs) for both HER2-positive breast cancer and triple-negative breast cancer (TNBC). This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.